GC녹십자는 질병관리본부의 코로나19 혈장 치료제 개발을 위한 연구용역 과제에 우선순위 협상대상자로 최종 선정됐다고 4일 밝혔다.
GC Green Cross announced on the 4th that it was finally selected as a priority negotiator for the research service project for the development of plasma treatment for COVID-19 by the Korea Centers for Disease Control and Prevention.